Filter By Category
Archives
Share on -
ASTEGOLIMAB
Generic Name: ASTEGOLIMAB
ABSTRACT -
Astegolimab is a fully human IgG2 monoclonal antibody targeting ST2 (IL1RL1), the receptor component for interleukin-33 signaling. By blocking IL-33/ST2 activity, it is intended to reduce type-2 and epithelial alarmin-driven inflammation. It has been studied in asthma, COPD, and other inflammatory-disease research settings.
DOSAGE -
No approved standard dosage is established. Clinical studies have used subcutaneous or intravenous protocol-defined regimens depending on indication. Dose interval, monitoring, and discontinuation rules must follow the trial design.
SIDE EFFECTS–
- Possible or reported side effects may include:
- Injection-site or infusion-site reactions
- Headache
- Upper respiratory infection
- Nasopharyngitis
- Fatigue
- Rash or pruritus
- Possible infection risk
- Laboratory abnormalities
ALLERGIC REACTIONS -
Hypersensitivity reactions may include hives, swelling, dyspnea, wheeze, hypotension, or anaphylaxis.
DRUG INTERACTIONS-
Use caution with:
- Other biologics for asthma/COPD
- Systemic corticosteroids or immunosuppressants
- Live vaccines
- Other investigational medicines
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, and supplements they are using.
PREAUTIONS–
- Assess infection status, asthma/COPD control, eosinophilic/type-2 biomarkers when relevant, pregnancy status, and prior biologic exposure.
- Do not use for acute bronchospasm.
- Monitor for infections and hypersensitivity.
WARNINGS –
- Not a rescue medicine for acute respiratory symptoms.
- Use only under clinical-trial or specialist supervision.
- Keep out of reach of children.
- In case of overdose, severe reaction, or clinical deterioration, seek immediate medical attention.
Share on -
. Developed by